Dinesh Kumar Chellappan1, Kun Hooi Leng2, Lee Jia Jia2, Nur Amirah Binti Abdul Aziz2, Wong Chun Hoong2, Yap Cheng Qian2, Fam Yi Ling2, Gwee Sing Wei2, Tiong Ying2, Jestin Chellian3, Gaurav Gupta4, Kamal Dua5. 1. Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia. Electronic address: dinesh_kumar@imu.edu.my. 2. School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia. 3. Department of Life Sciences, School of Pharmacy, International Medical University, Kuala Lumpur 57000, Malaysia. 4. School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, 302017, Jaipur, India. Electronic address: gauravpharma25@gmail.com. 5. Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW 2007, Australia.
Abstract
OBJECTIVE: The study aims to analyze the effectiveness of bevacizumab in addressing the complications associated with gynecological cancers and evaluates effective treatments for various gynecological cancers. METHODS: The study follows a systematic review approach that has been implemented to analyze the qualitative published data from previous studies. Studies related with the trials of angiogenesis and bevacizumab were selected in the review. RESULTS: In general, the management of gynecological cancers include chemotherapy, surgery and radiation therapy. Results suggest bevacizumab as an effective treatment modality for cervical and several other cancers. Overall, bevacizumab showed promising results in improving the overall survival rate of gynecological cancer patients through the combination of bevacizumab with other chemotherapeutic agents. CONCLUSION: Bevacizumab possess less documented adverse effects when compared to other chemotherapeutic agents. The manifestation and severity of adverse effects reported varied according to the chemotherapeutic agent(s) that were used with bevacizumab in combination therapy. Overall, bevacizumab effectively improved the survival rate in patients with several gynaecological cancers.
OBJECTIVE: The study aims to analyze the effectiveness of bevacizumab in addressing the complications associated with gynecological cancers and evaluates effective treatments for various gynecological cancers. METHODS: The study follows a systematic review approach that has been implemented to analyze the qualitative published data from previous studies. Studies related with the trials of angiogenesis and bevacizumab were selected in the review. RESULTS: In general, the management of gynecological cancers include chemotherapy, surgery and radiation therapy. Results suggest bevacizumab as an effective treatment modality for cervical and several other cancers. Overall, bevacizumab showed promising results in improving the overall survival rate of gynecological cancerpatients through the combination of bevacizumab with other chemotherapeutic agents. CONCLUSION:Bevacizumab possess less documented adverse effects when compared to other chemotherapeutic agents. The manifestation and severity of adverse effects reported varied according to the chemotherapeutic agent(s) that were used with bevacizumab in combination therapy. Overall, bevacizumab effectively improved the survival rate in patients with several gynaecological cancers.
Authors: Jean Bouquet de Joliniere; Arrigo Fruscalzo; Fathi Khomsi; Emanuela Stochino Loi; Floryn Cherbanyk; Jean Marc Ayoubi; Anis Feki Journal: Front Surg Date: 2021-12-06